Search results
Results from the WOW.Com Content Network
Glycation is the non-enzymatic process responsible for many (e.g. micro and macrovascular) complications in diabetes mellitus and is implicated in some diseases and in aging. [ 2 ] [ 3 ] [ 4 ] Glycation end products are believed to play a causative role in the vascular complications of diabetes mellitus .
Glycosylation also plays a role in cell-to-cell adhesion (a mechanism employed by cells of the immune system) via sugar-binding proteins called lectins, which recognize specific carbohydrate moieties. [2] Glycosylation is an important parameter in the optimization of many glycoprotein-based drugs such as monoclonal antibodies. [6]
The different types of lipid-linked oligosaccharide (LLO) precursor produced in different organisms.. N-linked glycosylation is the attachment of an oligosaccharide, a carbohydrate consisting of several sugar molecules, sometimes also referred to as glycan, to a nitrogen atom (the amide nitrogen of an asparagine (Asn) residue of a protein), in a process called N-glycosylation, studied in ...
Thus modified, these proteins contribute to complications from diabetes. AGEs affect nearly every type of cell and molecule in the body and are thought to be one factor in aging [6] and some age-related chronic diseases. [7] [8] [9] They are also believed to play a causative role in the vascular complications of diabetes mellitus. [10]
Type 2 diabetes is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through urination.
The human FOLH1 gene is positioned at the 11p11.12 locus of chromosome 11. The gene is 4,110 base pairs in length and composed of 22 exons. The encoded protein is a member of the M28 peptidase family. Orthologs of the human FOLH1 gene have also been identified in other mammals, including the 7 D3; 7 48.51 cM locus in mice. [16]
SGLT2 inhibitors are used in the treatment of type 2 diabetes. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with type 2 diabetes. [2] [3] As of 2014, several medications of this class had been approved or were under development. [4]
O-linked glycosylation is the attachment of a sugar molecule to the oxygen atom of serine (Ser) or threonine (Thr) residues in a protein. O -glycosylation is a post-translational modification that occurs after the protein has been synthesised.